|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Michael Ramroth||Chairman of the Management Board, CEO & CFO||956k||N/D||1961|
|Dr. Georg Floß||COO & Member of the Board of Management||838k||N/D||N/D|
|Dr. Monika Buttkereit||Head of Investor Relations||N/D||N/D||N/D|
|Dr. Christina Erb||Head of Corp. HR||N/D||N/D||N/D|
|Dr. Katrin BernÃ¶ster||Head of the Project Management Organisation||N/D||N/D||N/D|
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company's products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.
L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.